JP2024508753A - 製造及び療法への使用のために改変されたｄｎａｓｅ１－ｌｉｋｅ２ - Google Patents

製造及び療法への使用のために改変されたｄｎａｓｅ１－ｌｉｋｅ２ Download PDF

Info

Publication number
JP2024508753A
JP2024508753A JP2023549596A JP2023549596A JP2024508753A JP 2024508753 A JP2024508753 A JP 2024508753A JP 2023549596 A JP2023549596 A JP 2023549596A JP 2023549596 A JP2023549596 A JP 2023549596A JP 2024508753 A JP2024508753 A JP 2024508753A
Authority
JP
Japan
Prior art keywords
enzyme
subject
seq
pharmaceutical composition
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508753A5 (enExample
Inventor
トビアス エー． フックス
アンジェリン プラサンナ
Original Assignee
ニュートロリス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニュートロリス インコーポレイテッド filed Critical ニュートロリス インコーポレイテッド
Publication of JP2024508753A publication Critical patent/JP2024508753A/ja
Publication of JP2024508753A5 publication Critical patent/JP2024508753A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2023549596A 2021-02-17 2022-02-17 製造及び療法への使用のために改変されたｄｎａｓｅ１－ｌｉｋｅ２ Pending JP2024508753A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150433P 2021-02-17 2021-02-17
US63/150,433 2021-02-17
PCT/US2022/016771 WO2022178110A2 (en) 2021-02-17 2022-02-17 Dnase 1-like 2 engineered for manufacturing and use in therapy

Publications (2)

Publication Number Publication Date
JP2024508753A true JP2024508753A (ja) 2024-02-28
JP2024508753A5 JP2024508753A5 (enExample) 2025-02-19

Family

ID=82932330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549596A Pending JP2024508753A (ja) 2021-02-17 2022-02-17 製造及び療法への使用のために改変されたｄｎａｓｅ１－ｌｉｋｅ２

Country Status (6)

Country Link
US (1) US20240228995A9 (enExample)
EP (1) EP4294824A4 (enExample)
JP (1) JP2024508753A (enExample)
KR (1) KR20240004247A (enExample)
CN (1) CN117177990A (enExample)
WO (1) WO2022178110A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112996911A (zh) * 2018-10-08 2021-06-18 纽特雷斯股份有限公司 用于制造和疗法的脱氧核糖核酸酶的工程改造

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
UA129696C2 (uk) * 2017-08-18 2025-07-09 Ньютроліс Інк. СКОНСТРУЙОВАНІ ФЕРМЕНТИ ДНКази ТА ЇХНЄ ЗАСТОСУВАННЯ В ТЕРАПІЇ
AU2018393110B2 (en) * 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
CN112996911A (zh) * 2018-10-08 2021-06-18 纽特雷斯股份有限公司 用于制造和疗法的脱氧核糖核酸酶的工程改造

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMISTRY, vol. Vol.40, pp.143-152, JPN6026009081, 2001, ISSN: 0005813088 *
GENOMICS, vol. Vol.84, pp.95-105, JPN6026009080, 2004, ISSN: 0005813087 *

Also Published As

Publication number Publication date
KR20240004247A (ko) 2024-01-11
WO2022178110A3 (en) 2022-10-27
US20240132863A1 (en) 2024-04-25
EP4294824A4 (en) 2025-01-01
CN117177990A (zh) 2023-12-05
EP4294824A2 (en) 2023-12-27
US20240228995A9 (en) 2024-07-11
WO2022178110A2 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
JP3468778B2 (ja) ヒトｄｎアーゼｉ過反応性変異体
US7968512B2 (en) Conjugates that contain the homeodomain of antennapedia
CN1461308A (zh) 基于亮氨酸的基序和梭菌神经毒素
ES2240167T3 (es) Polipeptido con actividad fibrinolitica.
KR20230017804A (ko) Rhfgf21 융합 단백질, rhfgf21 융합 단백질을 인코딩하는 폴리뉴클레오티드, rhfgf21 융합 단백질을 포함하는 조성물, 및 rhfgf21 융합 단백질의 용도
CN101914561A (zh) 一种具有抗菌和修复功能的融合蛋白及其生产方法和应用
US20120015886A1 (en) Method for preparing recombinant peptide from spider venom and method for relieving pain
US20240228995A9 (en) Dnase 1-like 2 engineered for manufacturing and use in therapy
JP2000505285A (ja) ヒトｄｎアーゼ
JP5185914B2 (ja) ヒトｄｎアーゼｉｉ
JP2014529395A (ja) ボツリヌス神経毒のタンパク質分解的切断の改変
JPH07503367A (ja) ヒト　アポリポタンパク質ａｉｖから透導されたポリペプチド，その製造及びその利用
EP1497326B1 (en) Prothrombin activating protein
JPH07502652A (ja) シグナルペプチドを有さないスタフィロキナーゼの発現
US20170204393A1 (en) Thermally Stable Enzymes, Compositions Thereof and Method of Using Same
JP2024508753A5 (enExample)
JP2002508151A (ja) 哺乳類乳汁成長因子
US12150976B2 (en) Treatment of immune dysregulation disorders
ES2702358T3 (es) Uso de proteasas aspárticas vegetales para el tratamiento de afecciones de la piel
KR20180109272A (ko) 세포투과성 펩타이드와 ctCTLA4 펩타이드가 융합된 융합단백질을 유효성분으로 하는 염증성 호흡기 질환 예방 또는 치료용 약학 조성물
CN110183529B (zh) 一种缺失型人角质细胞生长因子-1的重组制备方法
JP3571371B2 (ja) オプソニン活性を有する新規な蛋白質
WO2025007838A1 (zh) Klk1融合蛋白的制备方法
JPH09503646A (ja) アンチトロンビンポリペプチド類似体及びその製造法
JPH0775573A (ja) ヒトカテプシンの製造法および該酵素含有製剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231013

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20231013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260723